Home The Word Brain My Amedeo FAQ Privacy About


Amedeo Chinese

For Medical Students & Physicians

A complete 20-lesson, 300-page Chinese course with a companion app in 21 languages — free forever.

Download the free PDF: Amedeo Chinese PDF

  Inflammatory Bowel Diseases

  Free Subscription


28.09.2026

4 Aliment Pharmacol Ther
1 Clin Exp Immunol
3 Clin Gastroenterol Hepatol
1 Drugs
3 Eur J Gastroenterol Hepatol
4 Inflamm Bowel Dis
6 J Crohns Colitis
2 PLoS One
1 Scand J Gastroenterol


   Retrieve available abstracts of this week’s articles:
HTML format
 
 
Single Articles


    Aliment Pharmacol Ther

  1. LEDING C, Meddis A, Holler JG, Burisch J, et al
    Pathogen-Specific Bloodstream Infections Associated With Tumour Necrosis Factor-alpha Inhibitors, Vedolizumab and Ustekinumab in Inflammatory Bowel Disease: A Danish Nationwide Case-Control Study 2010-2024.
    Aliment Pharmacol Ther. 2026 Sep 24. doi: 10.1111/apt.70999.
    PubMed         Abstract available

  2. YAGUE CABALLERO C, Garcia-Lopez S, Casas-Deza D
    Editorial: Treatment Sequencing in Inflammatory Bowel Disease-Does the Line Matter More Than the Mechanism? Authors' Reply.
    Aliment Pharmacol Ther. 2026 Sep 22. doi: 10.1111/apt.71006.
    PubMed        

  3. TRUNIGER S, Brand S
    Editorial: Anti-Integrin alphavbeta6 Autoantibodies for Distinguishing Ulcerative Colitis From Crohn's Disease: Authors' Reply.
    Aliment Pharmacol Ther. 2026 Sep 22. doi: 10.1111/apt.71002.
    PubMed        

  4. MOHTA S, Kutum R, Dhoundiyal A, Pendyala R, et al
    Development and Prospective Validation of a Machine Learning-Based Mobile Application (CROHN'S AID) for Differentiating Crohn's Disease From Intestinal Tuberculosis in Tuberculosis-Endemic Regions.
    Aliment Pharmacol Ther. 2026 Sep 21. doi: 10.1111/apt.70984.
    PubMed         Abstract available


    Clin Exp Immunol

  5. HONJO H, Watanabe T, Otsuka Y, Masuta Y, et al
    Nucleotide-binding oligomerization domain 2-independent colonization by Turicimonas muris induced by high-fat diet protects against dextran sodium sulfate-induced colitis.
    Clin Exp Immunol. 2026;220:uxag057.
    PubMed         Abstract available


    Clin Gastroenterol Hepatol

  6. R G, R F, N G, S C, et al
    Janus Kinase Inhibitors for Acute Severe Ulcerative Colitis: Comparing Upadacitinib to Tofacitinib and Rescue to Sequential Salvage therapy.
    Clin Gastroenterol Hepatol. 2026 Sep 22:S1542-3565(26)00719.
    PubMed         Abstract available

  7. DALAL RS, Silvestri ME, Kwaning KM, Carlin AD, et al
    Guselkumab Versus Risankizumab for Ulcerative Colitis: Real-World Comparison of Post-Induction Outcomes.
    Clin Gastroenterol Hepatol. 2026 Sep 23:S1542-3565(26)00721.
    PubMed        

  8. GOYAL MK, Lee A, Shah D, Brehmer S, et al
    Managing IBS-Like Symptoms in Quiescent Inflammatory Bowel Disease: A Meta-Analysis of Randomized Trials.
    Clin Gastroenterol Hepatol. 2026 Sep 25:S1542-3565(26)00725.
    PubMed         Abstract available


    Drugs

  9. FAGGIANI I, Tuttle C, Danese S, Peyrin-Biroulet L, et al
    Antibiotic-Refractory Chronic Pouchitis After Ileal Pouch-Anal Anastomosis: Current and Emerging Therapeutic Strategies.
    Drugs. 2026;86:1577-1597.
    PubMed         Abstract available


    Eur J Gastroenterol Hepatol

  10. DIVAKARLA S, Hinckfuss C, Cruz C, Luo H, et al
    The role of bioelectrical impedance analysis in assessing sarcopenia in inflammatory bowel disease.
    Eur J Gastroenterol Hepatol. 2026 Aug 12. doi: 10.1097/MEG.0000000000003265.
    PubMed         Abstract available

  11. NAPOLITANO D, Bozzetti M, Scaldaferri F, Gasbarrini A, et al
    Generational differences in illness perception among adults with inflammatory bowel disease: a multicenter cross-sectional study.
    Eur J Gastroenterol Hepatol. 2026 Aug 27. doi: 10.1097/MEG.0000000000003266.
    PubMed         Abstract available

  12. SABHAN H, Bello F, Muhsen S, Johansson F, et al
    Early but not serial ustekinumab concentration measurements are associated with clinical outcomes in Crohn's disease and ulcerative colitis: the Stockholm Ustekinumab study (STOCUSTE).
    Eur J Gastroenterol Hepatol. 2026 Sep 1. doi: 10.1097/MEG.0000000000003274.
    PubMed         Abstract available


    Inflamm Bowel Dis

  13. HE D, Sha S, Liu X, Yin P, et al
    Comparative effectiveness of infliximab vs vedolizumab as first-line biologic therapy in moderate-to-severe ulcerative colitis: A prospective, multicenter, real-world study.
    Inflamm Bowel Dis. 2026 Sep 23:izag185. doi: 10.1093.
    PubMed         Abstract available

  14. LE BERRE C, Rezazadeh Ardabili A, Czepielewski R, Cices A, et al
    Revisiting the role of lymphatics in Crohn's disease.
    Inflamm Bowel Dis. 2026 Sep 23:izag187. doi: 10.1093.
    PubMed         Abstract available

  15. EDELMAN-KLAPPER H, Avni-Biron I, Ollech JE, Hegger S, et al
    Long-term outcomes of patients with negative small bowel video capsule endoscopy for Crohn's disease: A cohort study.
    Inflamm Bowel Dis. 2026 Sep 24:izag188. doi: 10.1093.
    PubMed         Abstract available

  16. GISBERT JP, Chaparro M
    Biologics, small molecules, and extraintestinal malignancies in inflammatory bowel disease: practical questions and evidence-based answers.
    Inflamm Bowel Dis. 2026 Sep 25:izag192. doi: 10.1093.
    PubMed         Abstract available


    J Crohns Colitis

  17. JACOBS I, Ceulemans M, Lenfant M, Cremer J, et al
    Distinct intestinal eosinophil subsets in ulcerative colitis and their modulation by advanced inflammatory bowel disease therapies.
    J Crohns Colitis. 2026;20:jjag141.
    PubMed         Abstract available

  18. SRINIVASAN AR, Sagami S, Nguyen A, Smith RL, et al
    Evaluating sonographic response and remission in inflammatory bowel disease: aligning intestinal ultrasound assessment with STRIDE-II timelines.
    J Crohns Colitis. 2026;20:jjag132.
    PubMed         Abstract available

  19. LEES RD, Patel P, Young G, Beck L, et al
    Orofacial granulomatosis associated with Crohn's disease: clinical phenotype and response to biologics and Janus kinase inhibitor therapy in a large multi-center cohort.
    J Crohns Colitis. 2026;20:jjag139.
    PubMed         Abstract available

  20. SPENCER EA, Cohen S, Dubinsky MC, Suskind DL, et al
    Upadacitinib treatment in pediatric Crohn's disease: 52-week outcomes of an international multicenter retrospective cohort study from the pediatric IBD Porto Group of ESPGHAN.
    J Crohns Colitis. 2026;20:jjag125.
    PubMed         Abstract available

  21. KATANO T, Okabayashi S, Yamazaki H, Matsubayashi M, et al
    Effectiveness and safety of tacrolimus versus infliximab as rescue therapy for intravenous corticosteroid-refractory acute severe ulcerative colitis: a multicenter cohort study.
    J Crohns Colitis. 2026;20:jjag143.
    PubMed         Abstract available

  22. GADEOCK S, King M, Polk DB, Highton AJ, et al
    Targeting epithelial IFN-I signaling restores barrier integrity in anti-TNF refractory Crohn's disease.
    J Crohns Colitis. 2026;20:jjag140.
    PubMed         Abstract available


    PLoS One

  23. SU Y, Luo X, Xu H
    Correction: Apoptosis-related genes bridge inflammatory bowel disease and osteoporosis: A bioinformatic analysis.
    PLoS One. 2026;21:e0359291.
    PubMed         Abstract available

  24. KAZI MAI, Mufarrih SM, Sirohi A, Hasan F, et al
    Cardiovascular outcomes associated With GLP-1 and dual GLP-1/GIP receptor agonists in patients with type 2 diabetes and inflammatory bowel disease: A retrospective real-world cohort study.
    PLoS One. 2026;21:e0358659.
    PubMed         Abstract available


    Scand J Gastroenterol

  25. SOUAID C, Buisson A, Jeay M, Skinazi F, et al
    Exploring obstacles to physical activity in inflammatory bowel disease: insights from a survey.
    Scand J Gastroenterol. 2026 Sep 24:1-3. doi: 10.1080/00365521.2026.2736875.
    PubMed         Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Inflammatory Bowel Diseases is free of charge.

Privacy / Datenschutzerklärung | Imprint / Impressum